Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply

被引：0
|
作者：
Ellis, Matthew J. [1 ]
Robertson, John F. R. [2 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Nottingham, Derby, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 16期
关键词：
FULVESTRANT; 500; MG; ANASTROZOLE; TRIAL; 1ST;
D O I：
10.1200/JCO.2016.66.6727
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1960 / +
页数：3
相关论文
共 50 条
  • [21] Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review
    Zhang, Nengying
    Luo, Chengmin
    Li, Jiayang
    Bao, Yuxiang
    Yan, Zhongliang
    Cheng, Xiaoming
    Li, Taolang
    Lv, Junyuan
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [22] Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer
    Kantor, Olga
    Wakeman, Melia
    Weiss, Anna
    Wong, Stephanie
    Laws, Alison
    Grossmith, Samantha
    Mittendorf, Elizabeth A.
    King, Tari A.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (03) : 1358 - 1367
  • [23] Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea
    Beom, Seung Hoon
    Oh, Jisu
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Yang, Yaewon
    Suh, Koung Jin
    Moon, Hyeong-Gon
    Han, Sae-Won
    Oh, Do-Youn
    Han, Wonshik
    Kim, Tae-You
    Noh, Dong-Young
    Im, Seock-Ah
    CANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 454 - 463
  • [24] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Tatsunori Shimoi
    Yasuaki Sagara
    Fumikata Hara
    Tatsuya Toyama
    Hiroji Iwata
    Breast Cancer, 2020, 27 : 340 - 346
  • [25] Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
    Rugo, Hope S.
    Rumble, R. Bryan
    Macrae, Erin
    Barton, Debra L.
    Connolly, Hannah Klein
    Dickler, Maura N.
    Fallowfield, Lesley
    Fowble, Barbara
    Ingle, James N.
    Jahanzeb, Mohammad
    Johnston, Stephen R. D.
    Korde, Larissa A.
    Khatcheressian, James L.
    Mehta, Rita S.
    Muss, Hyman B.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 3069 - +
  • [26] Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2-Advanced Breast Cancer?
    Malorni, Luca
    Biganzoli, Laura
    BREAST CARE, 2017, 12 (05) : 288 - 289
  • [27] Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
    Reinert, Tomas
    Barrios, Carlos H.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (11) : 693 - 709
  • [28] Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer
    Chia, Stephen
    Gradishar, William
    BREAST, 2008, 17 : S16 - S21
  • [29] Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
    Yuan, Yang
    Zhang, Shaohua
    Yan, Min
    Yin, Yongmei
    Song, Yuhua
    Jiang, Zefei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (10)
  • [30] Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
    Anishka D’Souza
    Darcy Spicer
    Janice Lu
    Journal of Hematology & Oncology, 11
12345